Author:
Corrao Giulia,Marvaso Giulia,Mastroleo Federico,Biffi Annalisa,Pellegrini Giacomo,Minari Samuele,Vincini Maria Giulia,Zaffaroni Mattia,Zerini Dario,Volpe Stefania,Gaito Simona,Mazzola Giovanni Carlo,Bergamaschi Luca,Cattani Federica,Petralia Giuseppe,Musi Gennaro,Ceci Francesco,De Cobelli Ottavio,Orecchia Roberto,Alterio Daniela,Jereczek-Fossa Barbara Alicja
Funder
Istituto Europeo di Oncologia
Ministero della Salute
Indigenous Bar Association
Reference203 articles.
1. Cancer statistics, 2022;Siegel;CA: a Cancer Journal for Clinicians,2022
2. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley;The Lancet Oncology,2016
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial;Widmark;Lancet,2019
4. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial;Brand;The Lancet Oncology,2019
5. NCCN guidelines® insights: prostate cancer, version 1.2023;Schaeffer;Journal of the National Comprehensive Cancer Network,2022